AB Science Valuation

Is A8D undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A8D when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A8D's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A8D's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for A8D?

Key metric: As A8D is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A8D. This is calculated by dividing A8D's market cap by their current revenue.
What is A8D's PS Ratio?
PS Ratio48.2x
Sales€1.08m
Market Cap€52.20m

Price to Sales Ratio vs Peers

How does A8D's PS Ratio compare to its peers?

The above table shows the PS ratio for A8D vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average12.7x
HIGH Cantourage Group
28.4x38.6%€55.6m
APPH Apontis Pharma
2x17.3%€80.3m
SBX SynBiotic
7.2x39.7%€27.9m
0RX Redx Pharma
13.3x-37.6%€65.0m
A8D AB Science
48.2xn/a€52.2m

Price-To-Sales vs Peers: A8D is expensive based on its Price-To-Sales Ratio (48.2x) compared to the peer average (12.7x).


Price to Sales Ratio vs Industry

How does A8D's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

23 CompaniesPrice / SalesEstimated GrowthMarket Cap
A8D 48.2xIndustry Avg. 2.9xNo. of Companies35PS0612182430+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A8D is expensive based on its Price-To-Sales Ratio (48.2x) compared to the European Pharmaceuticals industry average (2.9x).


Price to Sales Ratio vs Fair Ratio

What is A8D's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A8D PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio48.2x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A8D's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies